Table 2.
Retention in care at the end of 12‐month follow‐up period
| Variable | Retention outcome | |
|---|---|---|
| Not retained (n=266)a | Retained (n=1115)b | |
| Cohort (n = 1381), n (%) | ||
| Pre‐UTT | 111 (23.8) | 356 (76.2) |
| UTT | 155 (17.0) | 759 (83.0) |
| Age (n = 1381), n (%) | ||
| 10 to 19 | 20 (17.2) | 96 (82.8) |
| 20 to 24 | 43 (33.0) | 87 (66.9) |
| 25 to 49 | 177 (18.5) | 778 (81.5) |
| ≥ 50 | 26 (14.4) | 154 (85.6) |
| Gender category (n = 1381), n (%) | ||
| Femalec | 118 (16.5) | 599 (83.5) |
| Male | 95 (18.9) | 409 (81.1) |
| Pregnant/breastfeeding | 53 (33.1) | 107 (66.9) |
| Facility location (n = 1381), n (%) | ||
| Rural | 179 (18.5) | 786 (81.5) |
| Urban | 87 (21.0) | 329 (79.0) |
| TB status at ART initiation (n = 1350), n (%) | ||
| No | 240 (17.9) | 1099 (82.1) |
| Yes | 5 (45.5) | 6 (55.5) |
| Missing | 21 (67.7) | 10 (32.3) |
| WHO disease staging (n = 1381) | ||
| Stage I | 164 (18.0) | 747 (82.0) |
| Stage II | 25 (15.6) | 135 (84.4) |
| Stage III | 40 (21.6) | 145 (78.4) |
| Stage IV | 10 (27.8) | 26 (72.2) |
| Missing | 27 (30.3) | 62 (69.7) |
| BMI (n = 996), n (%) | ||
| ≤18.5 | 34 (17.9) | 156 (82.1) |
| 19 to 24.9 | 120 (18.0) | 547 (82.0) |
| 25 to 29.9 | 25 (20.5) | 97 (79.5) |
| 30 to 40 | 3 (17.7) | 14 (82.3) |
| Missing | 84 (21.8) | 301 (78.2) |
ART, antiretroviral therapy; BMI, body mass index; UTT, Universal Test and Treat; WHO, World Health Organization.
aNot retained: patients who were classified as LTFU, stopped ART or dead during the study period. bRetained: alive on ART at the end of 12‐month follow‐up period. cNot pregnant or breastfeeding at the time of starting ART.